HY-089

HY-089 is a repurposed small molecule therapeutic candidate under development by Hyloris Developments for the treatment of Burning Mouth Syndrome (BMS). BMS is a chronic condition characterized by a persistent burning sensation in the mouth, often without an identifiable physical cause, and currently lacks a gold-standard treatment. HY-089 is designed as a locally acting oral formulation, aiming to deliver the active agent directly to the affected oral tissues to maximize efficacy while minimizing systemic exposure. As a "Value Added Medicine," the program utilizes a well-characterized drug with an established safety profile, optimizing it for this specific indication. The candidate is currently in the preclinical stage of development.